CLASS II Device recall · Reported 18 Aug 2021 · FDA Enforcement Report

Myla software. Used to manage microbiology test workflow recalled

BioMerieux is recalling Myla software. Used to manage microbiology test workflow from the, distributed nationwide in the US. The recall was initiated on 22 Jun 2021 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesMYLA V4.8.0/4.8.1 and MYLA V4.7.0/V4.7.1 in conjunction with BCI CONNECT, UDI 03573026619244 and 03573026610975.
Quantity recalled248 systems

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2225-2021
FDA event ID
87985
Recalling firm
BioMerieux, Marcy L'Etoile, N/A
Classification
Class II
Status
Terminated
Recall initiated
22 Jun 2021
FDA classified
6 Aug 2021
Reported
18 Aug 2021
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Device Malfunction
Device type
Medical Software

Timeline

22 Jun 2021Recall initiated by company
6 Aug 2021Classified by FDA+45 days
18 Aug 2021Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Software anomaly - Under certain conditions, unwanted alterations to results could be applied when using the BCI Connect scripting feature.

Device recalls are issued when a component, software or design fault could cause the device to fail or give wrong readings. Many are corrections applied in the field rather than physical returns.

Product as listed by the FDA

MYLA software. Used to manage microbiology test workflow from the reception of requests to the transmission of results by transferring, storing, and displaying medical device data.

Where it was distributed

Distribution in the U.S. was nationwide. There was also military and government distribution.

Nationwide

Questions about this recall

Why was it recalled?

Software anomaly - Under certain conditions, unwanted alterations to results could be applied when using the BCI Connect scripting feature.

Which lots are affected?

MYLA V4.8.0/4.8.1 and MYLA V4.7.0/V4.7.1 in conjunction with BCI CONNECT, UDI 03573026619244 and 03573026610975.

Where was it sold?

Distribution in the U.S. was nationwide. There was also military and government distribution.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from BioMerieux

All 476

Other Medical Software recalls

All 903